NCT00226577View on ClinicalTrials.gov

Pharmacogenomic & Phase II Study of Gemcitabine and Pemetrexed in Non-Small-Cell Lung Cancer.

PHASE2CompletedINTERVENTIONAL
Enrollment

52

Participants

Timeline

Start Date

February 29, 2004

Primary Completion Date

December 31, 2008

Study Completion Date

December 31, 2008

Conditions
Lung Cancer
Interventions
DRUG

Gemcitabine

Gemcitabine (GemzarR) 1500 mg/m2

DRUG

Pemetrexed

Pemetrexed (AlimtaR) 500 mg/m2

PROCEDURE

Surgery

When the chemotherapy treatment is completed, the patient's tumor response will be evaluated by a CT scan, pulmonary function test, and another PET scan between days 50 and 63 (during weeks 8 and 9). If there is no growth or spread of the cancer on any of these tests, patients will then proceed to have surgery by week 10 to remove the cancer.

Trial Locations (1)

33612

H. Lee Moffitt Cancer Center & Research Institute, Tampa

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

collaborator

Eli Lilly and Company

INDUSTRY

lead

H. Lee Moffitt Cancer Center and Research Institute

OTHER

NCT00226577 - Pharmacogenomic & Phase II Study of Gemcitabine and Pemetrexed in Non-Small-Cell Lung Cancer. | Biotech Hunter | Biotech Hunter